


REMARKS

The above amendments serve to define certain preferred embodiments with greater particularity by:

- a) changing the dependency of claims 13, 15, 17, 18, 70 and 75;
- b) specifying that L¹ is pyridinyl in claims 32, 39, 46 and 47; and
- c) making claims 68 and 69 independent and not limited to cancers mediated by raf kinase.

The subject matter defined in claims 13, 15, 17 and 18 is still encompassed by claim 1 and the amendments do not add new matter. Support for the methods defined in claims 68 and 69 is found on page 2, lines 17-20.

Respectfully submitted,



Richard J. Traverso (Reg. No. 30,595)
Attorney for Applicant(s)

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Boulevard, Suite 1400
Arlington, Virginia 22201
(703) 812-5310 [Direct Dial]
E-mail address: traverso@mwzb.com

Filed: May 12, 2003

RJT/vb
K:\Bayer\24A\Submission with RCE 5-8-03.doc